These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 8386516)

  • 1. Efficacy of the herpes simplex virus types 1 and 2 mutant viruses to confer protection against zosteriform spread in mice.
    Mercadal CM; Slaoui M; Brown SM; Rouse BT
    Viral Immunol; 1993; 6(1):35-42. PubMed ID: 8386516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1.
    Morrison LA; Knipe DM
    Virology; 1997 Dec; 239(2):315-26. PubMed ID: 9434723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes.
    Manickan E; Rouse RJ; Yu Z; Wire WS; Rouse BT
    J Immunol; 1995 Jul; 155(1):259-65. PubMed ID: 7602102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge.
    Ghiasi H; Roopenian DC; Slanina S; Cai S; Nesburn AB; Wechsler SL
    Immunology; 1997 Jul; 91(3):430-5. PubMed ID: 9301533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted.
    Farrell HE; McLean CS; Harley C; Efstathiou S; Inglis S; Minson AC
    J Virol; 1994 Feb; 68(2):927-32. PubMed ID: 8289395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection against establishment of latent infections in mice immunized with a non-pathogenic herpes simplex virus mutant and reinfected with the pathogenic parental strain.
    Klein RJ; Kaley LA; Friedman-Kien AE
    Vaccine; 1984 Sep; 2(3):219-23. PubMed ID: 6099650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens.
    Karem KL; Bowen J; Kuklin N; Rouse BT
    J Gen Virol; 1997 Feb; 78 ( Pt 2)():427-34. PubMed ID: 9018066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination with the immediate-early protein ICP47 of herpes simplex virus-type 1 (HSV-1) induces virus-specific lymphoproliferation, but fails to protect against lethal challenge.
    Banks TA; Jenkins FJ; Kanangat S; Nair S; Dasgupta S; Foster CM; Rouse BT
    Virology; 1994 Apr; 200(1):236-45. PubMed ID: 8128625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of in vivo depletion of immunocyte populations on herpes simplex virus glycoprotein D vaccine-induced resistance to HSV2 challenge.
    Mishkin EM; Blasiak M; Giorgio D; Ishizaka ST
    Viral Immunol; 1992; 5(2):151-61. PubMed ID: 1319710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of protective immunity against herpes simplex virus with DNA encoding the immediate early protein ICP 27.
    Manickan E; Yu Z; Rouse RJ; Wire WS; Rouse BT
    Viral Immunol; 1995; 8(2):53-61. PubMed ID: 8825290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunized mice challenged with herpes simplex virus by the intranasal route show protection against latent infection.
    Rooney JF; Wohlenberg C; Cremer KJ; Notkins AL
    J Infect Dis; 1989 May; 159(5):974-6. PubMed ID: 2540251
    [No Abstract]   [Full Text] [Related]  

  • 12. Protection against zosteriform spread of herpes simplex virus by monoclonal antibodies.
    Mester JC; Glorioso JC; Rouse BT
    J Infect Dis; 1991 Feb; 163(2):263-9. PubMed ID: 1846388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
    Da Costa XJ; Morrison LA; Knipe DM
    Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection from oral herpes simplex virus infection by a nucleic acid-free virus vaccine.
    Kitces EN; Morahan PS; Tew JG; Murray BK
    Infect Immun; 1977 Jun; 16(3):955-60. PubMed ID: 197013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against ocular and cutaneous infection with herpes simplex virus type 1 by intragastric immunization with live virus.
    Irie H; Shimeld C; Williams N; Hill T
    J Gen Virol; 1993 Jul; 74 ( Pt 7)():1357-62. PubMed ID: 8393076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prepubertal vaccination of mice against experimental infection of the genital tract with type 2 herpes simplex virus.
    Skinner GR; Williams DR; Moles AW; Sargent A
    Arch Virol; 1980; 64(4):329-38. PubMed ID: 6249243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetically engineered herpes simplex virus vaccines.
    Watson RJ; Enquist LW
    Prog Med Virol; 1985; 31():84-108. PubMed ID: 2982176
    [No Abstract]   [Full Text] [Related]  

  • 18. Characterization of encephalitis in adult mice induced by intracerebral inoculation of herpes simplex virus type 1 (KOS) and comparison with mutants showing decreased virulence.
    Chrisp CE; Sunstrum JC; Averill DR; Levine M; Glorioso JC
    Lab Invest; 1989 Jun; 60(6):822-30. PubMed ID: 2543866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Design of inactivated polyvalent antiherpes vaccines].
    Andonov P; Dundarov S; Bakalov B
    Vopr Virusol; 1979; (6):665-71. PubMed ID: 230648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of interferon-gamma in immunity to herpes simplex virus.
    Yu Z; Manickan E; Rouse BT
    J Leukoc Biol; 1996 Oct; 60(4):528-32. PubMed ID: 8864138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.